A clinical trial demonstrated that adults from socioeconomically disadvantaged backgrounds were nearly three times more successful in quitting smoking with vaporized nicotine products (VNPs) compared to nicotine replacement therapy (NRT). Conducted in New South Wales, Australia, the study enrolled 1,045 daily smokers receiving government support and showed that 28.4% of VNP users achieved verified abstinence at a 7-month follow-up, compared to 9.6% in the NRT group. VNPs exhibited better adherence and fewer adverse events, indicating their potential as a preferred option for smoking cessation in these populations.

Source: Annals of Internal Medicine